SOHO 2021 | Novel approaches to treating AML in elderly patients
Tapan Kadia
• 26 Aug 2021
Tapan Kadia, MD, of The University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview of the treatment options for acute myeloid leukemia (AML) in elderly patients, as well as explaining how treatment differs between ages. Dr Kadia talks on the promising response rates demonstrated by the BCL-2 inhibitor venetoclax in combination with hypomethylating agents. Additionally, Dr Kadia talks on the use of double nucleoside analog therapy of cladribine and low-dose cytarabine alternating with decitabine as a backbone treatment to allow for further novel combinations. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
